AOD-9604

5mg Vial

29 August 2026Updated 29 August 2026

AOD-9604

Overview Research7 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for AOD-9604.

Create free account Member login

Full range of benefits for AOD-9604

Stimulates lipolysis (fat breakdown) in preclinical and some clinical studies

Inhibits lipogenesis (fat creation) in adipose tissue models

Enhances fatty-acid oxidation in adipocytes in preclinical research

Minimal activation of systemic GH/IGF-1 pathways at studied doses

Shown to reduce triglyceride accumulation in animal and pilot studies

Investigated as an adjunct to diet/exercise for body composition

Preclinical evidence of potential chondroprotective / cartilage effects

Generally well tolerated in short-term clinical safety studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 14 known interactions

Synergistic(3)Compatible(3)Monitor(4)Avoid(4)

Not recommended for concurrent use

Active malignancy or history of cancer

Use should be carefully evaluated or avoided because safety data are limited and theoretical risks related to tissue growth and repair cannot be excluded.

Pregnancy and breastfeeding

AOD-9604 should be avoided in pregnancy and lactation due to insufficient safety data for the foetus or infant.

Concurrent peptide regimens with overlapping endocrine effects (e.g., Ipamorelin, CJC-1295)

Combining with other peptides that influence growth hormone axes or metabolism requires specialist review because of potential additive endocrine or metabolic effects.

Anticoagulant therapy (warfarin, DOACs)

Although direct interactions are not documented, injectable therapy and potential metabolic effects warrant caution and consideration of bleeding risk and monitoring when used with anticoagulants.

All interaction categories

Synergistic (3)

Structured exercise (aerobic and resistance): Exercise enhances lipolysis and energy expenditure and is clinically complementary to AOD-9604's targeted fat-loss effects, improving overall adiposity reduction.
Calorie-restricted dietary program: A structured hypocaloric diet synergises with AOD-9604 by producing a negative energy balance that augments peptide-driven reductions in adipose tissue.
L-carnitine (adjunctive supplementation): L-carnitine supports mitochondrial fatty acid transport and may enhance lipid oxidation when combined with AOD-9604's lipolytic actions.

Compatible (3)

Oral multivitamin/micronutrient supplementation: Routine vitamin and mineral supplements have no known pharmacologic interaction with AOD-9604 and can be continued without special precautions.
Short-term NSAIDs (e.g., ibuprofen): There are no documented pharmacodynamic or metabolic interactions between NSAIDs and AOD-9604 for typical short-term analgesic use.
Topical dermatologic therapies: Topically applied dermatologic agents act locally and are not expected to interact systemically with subcutaneously administered AOD-9604.

Monitor (4)

Insulin (in patients with diabetes): Although AOD-9604 has limited systemic GH activity, glucose and insulin should be monitored in diabetic patients because changes in body composition and metabolism can alter glycaemic control.
Oral hypoglycaemic agents (metformin, sulfonylureas): Concomitant use with glucose-lowering drugs warrants monitoring of blood glucose and dose adjustment as weight and insulin sensitivity change during therapy.
Lipid-lowering therapies (statins, fibrates): When used as part of cardiometabolic risk management, lipid panels should be followed since combined therapy targets overlapping metabolic endpoints and may require regimen adjustment.
Growth hormone or GH secretagogues (somatropin, sermorelin, CJC-1295): Co-administration with GH or GH-releasing peptides requires monitoring of IGF‑1 and endocrine markers because additive or unanticipated endocrine effects are possible.

Avoid (4)

Active malignancy or history of cancer: Use should be carefully evaluated or avoided because safety data are limited and theoretical risks related to tissue growth and repair cannot be excluded.
Pregnancy and breastfeeding: AOD-9604 should be avoided in pregnancy and lactation due to insufficient safety data for the foetus or infant.
Concurrent peptide regimens with overlapping endocrine effects (e.g., Ipamorelin, CJC-1295): Combining with other peptides that influence growth hormone axes or metabolism requires specialist review because of potential additive endocrine or metabolic effects.
Anticoagulant therapy (warfarin, DOACs): Although direct interactions are not documented, injectable therapy and potential metabolic effects warrant caution and consideration of bleeding risk and monitoring when used with anticoagulants.